MedTrace Logo

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

NCT04805983 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-08-27

Study results available
· View outcomes & findings →

Summary

This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).

Conditions

  • Alzheimer Disease

Interventions

DRUG

BMS-984923

Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Adam Mecca, MD, PhD · Assistant Professor of Psychiatry; Associate Director, Alzheimer's Disease Research Unit; Faculty, Alzheimer's Disease Research Center (ADRC)

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-25
Primary Completion
2022-04-24
Completion
2022-04-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04805983 on ClinicalTrials.gov